Neumirna Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 8

Neumirna General Information

Description

Developer of RNA-based therapies designed for complex neurological diseases. The company's technology utilizes a proprietary platform for targeted intrathecal delivery of antisense oligonucleotides to modulate microRNAs, enabling healthcare professionals to provide disease-modifying treatments for patients with drug-resistant epilepsy and parkinson's disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • A.C. Meyers Vænge 15
  • 2450 Copenhagen
  • Denmark
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • A.C. Meyers Vænge 15
  • 2450 Copenhagen
  • Denmark

Neumirna Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neumirna Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator 16-Nov-2026 Completed Generating Revenue
4. Later Stage VC (Series A) 08-Jan-2025 Completed Generating Revenue
3. Grant 29-Feb-2024 Completed Generating Revenue
2. Grant 01-Aug-2023 $650K $1.21M Completed Generating Revenue
1. Early Stage VC 29-Nov-2021 $1.21M $1.21M Completed Generating Revenue
To view Neumirna’s complete valuation and funding history, request access »

Neumirna Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary 5,125 $136.34 $136.34 1x $136.34 2.64%
Ordinary 3,695 $109.07 $109.07 1x $109.07 1.91%
To view Neumirna’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Neumirna Patents

Neumirna Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026195666-A1 Treatment of comorbidities associated with epilepsy Pending 17-Mar-2025
WO-2026068729-A1 Antimir-27b for treatment of parkinson's disease Pending 26-Sep-2024
AU-2022329462-A1 Antisense oligonucleotides targeting adenosine kinase Inactive 19-Aug-2021
CA-3228833-A1 Antisense oligonucleotides targeting adenosine kinase Pending 19-Aug-2021
EP-4388096-A1 Antisense oligonucleotides targeting adenosine kinase Pending 19-Aug-2021 C12N15/1137
To view Neumirna’s complete patent history, request access »

Neumirna Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neumirna Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
European Innovation Council Accelerator/Incubator
Angelini Ventures Corporate Venture Capital Minority
Iaso Ventures Venture Capital Minority
Invivo Partners Venture Capital Minority
Welfare Tech Invest Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Neumirna FAQs

  • When was Neumirna founded?

    Neumirna was founded in 2020.

  • Where is Neumirna headquartered?

    Neumirna is headquartered in Copenhagen, Denmark.

  • What is the size of Neumirna?

    Neumirna has 18 total employees.

  • What industry is Neumirna in?

    Neumirna’s primary industry is Drug Discovery.

  • Is Neumirna a private or public company?

    Neumirna is a Private company.

  • What is Neumirna’s current revenue?

    The current revenue for Neumirna is .

  • How much funding has Neumirna raised over time?

    Neumirna has raised $24.5M.

  • Who are Neumirna’s investors?

    European Innovation Council, Angelini Ventures, Iaso Ventures, Invivo Partners, and Welfare Tech Invest are 5 of 8 investors who have invested in Neumirna.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process